A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/497 (2006.01) A61K 45/06 (2006.01) A61P 11/00 (2006.01) A61P 11/06 (2006.01) A61P 17/00 (2006.01) A61P 17/14 (2006.01) A61P 19/02 (2006.01) A61P 29/00 (2006.01) A61P 37/00 (2006.01) A61P 37/06 (2006.01)
Patent
CA 2695365
The present application discloses a method of treating a CXCR3 chemokine receptor mediated disease selected from the group consisting of chronic obstructive pulmonary disease (COPD), asthma, sarcoidosis, systemic lupus erythematosus (SLE), alkylosing spondylitis, fibrotic diseases, pulmonary fibrosis, alopecia areata, scleroderma, lichen planus erythematosus, discoid lupus erythematosus, dermatomyositis, Behcet's disease, Wegener's disease, atopic dermatitis, and graft-vs-host disease (GVHD) in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of at least one compound having the general structure shown in Formula 1: Formula 1 or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein.
Cette invention se rapporte à un procédé de traitement d'une maladie associée avec les récepteurs des chimiokines CXCR3 choisie dans le groupe constitué par la bronchopneumopathie chronique obstructive (BPCO), l'asthme, la sarcoïdose, le lupus érythémateux disséminé (LED), la spondylarthrite ankylosante, les maladies fibrotiques, la fibrose pulmonaire, la pelade, la sclérodermie, le lichen plan érythémateux, le lupus érythémateux chronique, la dermatomyosite, la maladie de Behçet, la maladie de Wegener, la dermite atopique et la réaction du greffon contre hôte (GvH), chez un patient nécessitant ce type de traitement et comprenant l'administration au patient d'une quantité thérapeutiquement efficace d'au moins un composé ayant la structure générale présentée en formule 1, ou son sel, solvate ou ester pharmaceutiquement acceptables, les différentes fractions étant définies dans la description.
Anilkumar Gopinadhan N.
Fine Jay S.
Hobbs Douglas W.
Kim Seong Heon
Kozlowski Joseph A.
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
Pharmacopeia Llc
Schering Corporation
LandOfFree
Method of treating cxcr3 mediated diseases using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating cxcr3 mediated diseases using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating cxcr3 mediated diseases using... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2004610